Dave Asprey, a biohacking influencer, tells his followers that nicotine can reverse Alzheimer’s and boost cognition. He joins a wave of health advocates tied to the Make America Healthy Again movement who market nicotine patches, gums, lozenges and pouches as “natural” wellness tools. Their rhetoric mirrors that of former pharma skeptics in early 2024 campaign.

U.S. sales of nicotine pouches nearly tripled between January 2023 and December 2024, a surge that fuels tobacco giants. Brands like ZYN and niche players such as Athletic Nicotine capitalize on the hype, positioning their products as harm‑reduction alternatives. The rise translates into higher revenue streams for companies that have shifted focus from cigarettes to snus‑style offerings in 2024 year.

Health experts warn that while nicotine can sharpen focus, it carries addiction risks and cardiovascular strain. Dr. Adam Leventhal cautions that first‑time users may develop dependence, and children face heightened brain‑development hazards. Regulatory bodies argue that the current marketing narrative overstates benefits, potentially undermining public health safeguards for smokeless product users across the nation today.

The influx of wellness‑oriented nicotine products reshapes the tobacco industry’s revenue model, pushing it toward lower‑risk, higher‑margin items. Investors eye the sector as sales climb, while policymakers grapple with balancing harm‑reduction messaging against addiction risks. Ultimately, the debate underscores how influencer narratives can drive market shifts even amid scientific uncertainty for future policy and investment decisions through 2025 and beyond.